1H AND 31P NMR OF HUMAN KIDNEY, HEART AND TUMORS

人类肾脏、心脏和肿瘤的 1H 和 31P NMR

• 批准号: 3231681
• 负责人: MICHAEL W WEINER
• 金额: $ 12.75万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1984
• 资助国家: 美国
• 起止时间: 1984-09-30 至 1992-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3231681
• 关键词: acidity /alkalinity; acute renal failure; clinical biomedical equipment; coronary occlusion /thrombosis; deuterium; diagnosis design /evaluation; disease /disorder model; electronic pacemaker; electronic spectra; exercise; glomerular filtration; head /neck neoplasm; heart contraction; heart metabolism; heart rate; heart transplantation; human subject; human therapy evaluation; hypertrophic myocardiopathy; ischemia; kidney metabolism; lactates; magnetic resonance imaging; molecular oncology; molecular pathology; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; nuclear magnetic resonance spectroscopy; phantom model; phosphates; squamous cell carcinoma; swine; ultrasonography

The goal of this project is to determine the metabolic disturbances within tissue produced by disease and therapy. High- energy phosphates, pH, lactate, and other metabolites will be measured in surface tumors, heart, and kidneys of human patients, using 31P and 1H NHR. Both Bo and B1 localization techniques will be developed, simulated, tested on phantoms, normal subjects, and patients. Cancer studies will examine the possibility that metabolic changes are a sensitive and early index of the response to therapy. These studies will begin with large superficial squamous cell carcinomas of the head and neck. After completing a survey to characterize metabolic composition, heterogeneity, and variability, pilot experiments will determine the effects and time course of chemo- and radiation therapy. A prospective trial will correlate the spectral changes with the ultimate response to therapy, determined by MRI, CT, and ultimate outcome. Heart studies are designed to test the hypothesis that disorders of cardiac energy metabolism may be responsible for functional abnormalities in cardiac disease. 31P and 1H NMR studies of coronary ischemia in the pig will be continued using surgically implanted coils. Spectral localization techniques will be developed using the pig and human subjects. The effects of exercise and pacing will be determined and the metabolic alterations produced by myocardiopathy, hypertrophy, transplant rejection, and ischemia will be examined. Human kidney studies are aimed at investigating the metabolic changes produced by acute tubular necrosis. Once localization techniques are developed, and the normal kidney is examined, the changes associated with acute tubular necrosis will be characterized. Renal function will be correlated with NMR results to determine if spectral changes predict the outcome, or the response to therapy in a series of patients with ATN.

该项目的目标是确定代谢 由疾病和治疗引起的组织内紊乱。 高的- 能量磷酸盐、pH、乳酸和其他代谢物将 在人类患者的表面肿瘤、心脏和肾脏中进行测量， 使用 31P 和 1H NHR。 Bo 和 B1 定位技术 将在模型上进行开发、模拟、测试，正常 受试者和患者。 癌症研究将检验这种可能性 代谢变化是一个敏感且早期的指标 对治疗的反应。 这些研究将从大范围开始 头颈部浅表鳞状细胞癌。 后 完成一项调查来表征代谢组成， 异质性和变异性，试点实验将确定 化疗和放射治疗的效果和时间进程。 一个 前瞻性试验将光谱变化与 对治疗的最终反应，由 MRI、CT 和 最终结果。 心脏研究旨在测试 假设心脏能量代谢紊乱可能是 负责心脏病的功能异常。 31P 猪冠状动脉缺血的 1H NMR 研究将 继续使用手术植入的线圈。 光谱定位 将使用猪和人类受试者来开发技术。 运动和节奏的效果将被确定，并且 心肌病、肥厚引起的代谢改变， 将检查移植排斥和缺血。 人类 肾脏研究旨在调查代谢变化 由急性肾小管坏死产生。 一旦定位技术 发育完成，检查正常肾脏，发现变化 与急性肾小管坏死相关的特征将被表征。 肾功能将与 NMR 结果相关联以确定 如果光谱变化预测结果或响应 对一系列 ATN 患者进行治疗。